


in which

R₁ represents a hydrogen atom or an alkyl group; and


R₂ represents a hydrogen atom; along with a pharmaceutically acceptable adjuvant.

2. (Amended) A pharmaceutical preparation containing as an effective component a compound represented by the following formula (I):




in which R₁ represents a hydrogen atom or an alkyl group and R₂ represents a hydrogen atom, in combination with a pharmaceutically acceptable auxiliary, diluent, isotonic agent, preservative, lubricant and solubilizing aid, which is formulated in the form of a pharmaceutically acceptable preparation and has a potent effect for osteoporosis, arthritis and ruptured disc.

3. (Amended) A pharmaceutical preparation containing as an effective component a compound represented by the following formula (I):



in which R_1 represents a hydrogen atom or an alkyl group and R_2 represents a hydrogen atom, and one more materials selected from the group consisting of allendrate, tamoxifen, vitamin D_3 , parathyroid hormone (PTH), sulfasalazine, thioredoxin reductase, alendronate, raloxifene, calcitonin, estradiol, genistein, 1,25-dihydroxyvitamin D_3 , estrogen receptor modulator, biphosphonates, shinbarometin and shinbarometin acetate, in combination with a pharmaceutically acceptable auxiliary, diluent, isotonic agent, preservative, lubricant and solubilizing aid, which is formulated in the form of a pharmaceutically acceptable preparation and has a potent effect for osteoporosis, arthritis and ruptured disc.

4. (Amended) A process for preparing a compound of formula (I) wherein R_2 is a hydrogen atom, comprising hydrolyzing the compound of formula (I) wherein R_2 is cinnamoyl:



(I)

in which R_1 represents a hydrogen atom or an alkyl group.